New data from Israel-based generics giant Teva Pharmaceutical Industries (NYSE: TEVA) show favorable patient and healthcare ...

More than 92% of schizophrenia patients taking Olanzapine LAI in the Phase 3 SOLARIS survey were satisfied or very satisfied with the initiation regimen, dosing schedule and trial medication 1. These ...

More than 92% of schizophrenia patients taking Olanzapine LAI in the Phase 3 SOLARIS survey were satisfied or very satisfied with the initiation regimen, dosing schedule and trial medication1.

(TEVA), today announced the presentation of a patient and healthcare professional (HCP) attitudes and experiences survey study, complementing the successful Phase 3 Subcutaneous Olanzapine ...

Results from the SOLARIS trial survey showed that over 92% of patients, 87% of nurses, and 72% of physicians expressed satisfaction with TEV-'749’s initiation regimen, dosing schedule, and overall ...

Tokyo prosecutors indicted one of two parents on charges of murdering their 4-year-old daughter, the fourth family member who ...

When a murder accused threatened and demanded money from an elderly man, whom he would later fatally assault, he was not ...